Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41


Novel functional proteins coded by the human genome discovered in metastases of melanoma patients.

Sanchez A, Kuras M, Murillo JR, Pla I, Pawlowski K, Szasz AM, Gil J, Nogueira FCS, Perez-Riverol Y, Eriksson J, Appelqvist R, Miliotis T, Kim Y, Baldetorp B, Ingvar C, Olsson H, Lundgren L, Ekedahl H, Horvatovich P, Sugihara Y, Welinder C, Wieslander E, Kwon HJ, Domont GB, Malm J, Rezeli M, Betancourt LH, Marko-Varga G.

Cell Biol Toxicol. 2019 Oct 10. doi: 10.1007/s10565-019-09494-4. [Epub ahead of print]


Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data.

Betancourt LH, Pawłowski K, Eriksson J, Szasz AM, Mitra S, Pla I, Welinder C, Ekedahl H, Broberg P, Appelqvist R, Yakovleva M, Sugihara Y, Miharada K, Ingvar C, Lundgren L, Baldetorp B, Olsson H, Rezeli M, Wieslander E, Horvatovich P, Malm J, Jönsson G, Marko-Varga G.

Sci Rep. 2019 Mar 26;9(1):5154. doi: 10.1038/s41598-019-41625-z.


Clinical protein science in translational medicine targeting malignant melanoma.

Gil J, Betancourt LH, Pla I, Sanchez A, Appelqvist R, Miliotis T, Kuras M, Oskolas H, Kim Y, Horvath Z, Eriksson J, Berge E, Burestedt E, Jönsson G, Baldetorp B, Ingvar C, Olsson H, Lundgren L, Horvatovich P, Murillo JR, Sugihara Y, Welinder C, Wieslander E, Lee B, Lindberg H, Pawłowski K, Kwon HJ, Doma V, Timar J, Karpati S, Szasz AM, Németh IB, Nishimura T, Corthals G, Rezeli M, Knudsen B, Malm J, Marko-Varga G.

Cell Biol Toxicol. 2019 Aug;35(4):293-332. doi: 10.1007/s10565-019-09468-6. Epub 2019 Mar 21.


Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.

Welinder C, Pawłowski K, Szasz AM, Yakovleva M, Sugihara Y, Malm J, Jönsson G, Ingvar C, Lundgren L, Baldetorp B, Olsson H, Rezeli M, Laurell T, Wieslander E, Marko-Varga G.

PLoS One. 2017 Apr 26;12(4):e0176167. doi: 10.1371/journal.pone.0176167. eCollection 2017.


Merging clinical chemistry biomarker data with a COPD database - building a clinical infrastructure for proteomic studies.

Eriksson J, Andersson S, Appelqvist R, Wieslander E, Truedsson M, Bugge M, Malm J, Dahlbäck M, Andersson B, Fehniger TE, Marko-Varga G.

Proteome Sci. 2017 Apr 21;15:8. doi: 10.1186/s12953-017-0116-2. eCollection 2016.


Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer.

Rasmusson E, Gunnlaugsson A, Kjellén E, Nilsson P, Einarsdottir M, Wieslander E, Fransson P, Ahlgen G, Blom R.

Acta Oncol. 2016 Aug;55(8):1016-21. doi: 10.1080/0284186X.2016.1175659. Epub 2016 May 13.


Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study.

Truedsson M, Malm J, Barbara Sahlin K, Bugge M, Wieslander E, Dahlbäck M, Appelqvist R, Fehniger TE, Marko-Varga G.

Clin Transl Med. 2016 Mar;5(1):9. doi: 10.1186/s40169-016-0086-5. Epub 2016 Mar 7.


A protein deep sequencing evaluation of metastatic melanoma tissues.

Welinder C, Pawłowski K, Sugihara Y, Yakovleva M, Jönsson G, Ingvar C, Lundgren L, Baldetorp B, Olsson H, Rezeli M, Jansson B, Laurell T, Fehniger T, Döme B, Malm J, Wieslander E, Nishimura T, Marko-Varga G.

PLoS One. 2015 Apr 13;10(4):e0123661. doi: 10.1371/journal.pone.0123661. eCollection 2015.


Analysis of alpha-synuclein in malignant melanoma - development of a SRM quantification assay.

Welinder C, Jönsson GB, Ingvar C, Lundgren L, Baldetorp B, Olsson H, Breslin T, Rezeli M, Jansson B, Fehniger TE, Laurell T, Wieslander E, Pawlowski K, Marko-Varga G.

PLoS One. 2014 Oct 21;9(10):e110804. doi: 10.1371/journal.pone.0110804. eCollection 2014.


A new look at drugs targeting malignant melanoma--an application for mass spectrometry imaging.

Sugihara Y, Végvári A, Welinder C, Jönsson G, Ingvar C, Lundgren L, Olsson H, Breslin T, Wieslander E, Laurell T, Rezeli M, Jansson B, Nishimura T, Fehniger TE, Baldetorp B, Marko-Varga G.

Proteomics. 2014 Sep;14(17-18):1963-70. doi: 10.1002/pmic.201300476. Epub 2014 Aug 18. Review.


Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification.

Welinder C, Jönsson G, Ingvar C, Lundgren L, Baldetorp B, Olsson H, Breslin T, Rezeli M, Jansson B, Laurell T, Fehniger TE, Wieslander E, Pawlowski K, Marko-Varga G.

J Proteome Res. 2014 Mar 7;13(3):1315-26. doi: 10.1021/pr400876p. Epub 2014 Feb 17.


Standardization developments for large scale biobanks in smoking related diseases - a model system for blood sample processing and storage.

Malm J, Fehniger TE, Danmyr P, Végvári Á, Welinder C, Lindberg H, Upton P, Carter S, Appelqvist R, Sjödin K, Wieslander E, Dahlbäck M, Rezeli M, Erlinge D, Marko-Varga G.

Transl Respir Med. 2013 Dec;1(1):14. doi: 10.1186/2213-0802-1-14. Epub 2013 Aug 30.


Anti-inflammatory effects of budesonide in human lung fibroblast are independent of histone deacetylase 2.

Wang X, Nelson A, Weiler ZM, Patil A, Sato T, Kanaji N, Nakanishi M, Michalski J, Farid M, Basma H, Levan TD, Miller-Larsson A, Wieslander E, Muller KC, Holz O, Magnussen H, Rabe KF, Liu X, Rennard SI.

J Inflamm Res. 2013 Aug 20;6:109-19. doi: 10.2147/JIR.S43736. eCollection 2013.


Developments in biobanking workflow standardization providing sample integrity and stability.

Malm J, Fehniger TE, Danmyr P, Végvári A, Welinder C, Lindberg H, Appelqvist R, Sjödin K, Wieslander E, Laurell T, Hober S, Berven FS, Fenyö D, Wang X, Andrén PE, Edula G, Carlsohn E, Fuentes M, Nilsson CL, Dahlbäck M, Rezeli M, Erlinge D, Marko-Varga G.

J Proteomics. 2013 Dec 16;95:38-45. doi: 10.1016/j.jprot.2013.06.035. Epub 2013 Jul 13.


Effect of budesonide on fibroblast-mediated collagen gel contraction and degradation.

Fang Q, Schulte NA, Kim H, Kobayashi T, Wang X, Miller-Larsson A, Wieslander E, Toews ML, Liu X, Rennard SI.

J Inflamm Res. 2013;6:25-33. doi: 10.2147/JIR.S35136. Epub 2013 Feb 27.


Enhanced ROCK1 dependent contractility in fibroblast from chronic obstructive pulmonary disease patients.

Hallgren O, Rolandsson S, Andersson-Sjöland A, Nihlberg K, Wieslander E, Kvist-Reimer M, Dahlbäck M, Eriksson L, Bjermer L, Erjefält JS, Löfdahl CG, Westergren-Thorsson G.

J Transl Med. 2012 Aug 22;10:171. doi: 10.1186/1479-5876-10-171.


Influence of dose calculation algorithms on the predicted dose distribution and NTCP values for NSCLC patients.

Nielsen TB, Wieslander E, Fogliata A, Nielsen M, Hansen O, Brink C.

Med Phys. 2011 May;38(5):2412-8.


A Monte Carlo study of a flattening filter-free linear accelerator verified with measurements.

Dalaryd M, Kragl G, Ceberg C, Georg D, McClean B, af Wetterstedt S, Wieslander E, Knöös T.

Phys Med Biol. 2010 Dec 7;55(23):7333-44. doi: 10.1088/0031-9155/55/23/010. Epub 2010 Nov 16.


Charged fusion product loss measurements using nuclear activation.

Bonheure G, Hult M, González de Orduña R, Arnold D, Dombrowski H, Laubenstein M, Wieslander E, Vermaercke P, Murari A, Popovichev S, Mlynar J; JET-EFDA Contributors.

Rev Sci Instrum. 2010 Oct;81(10):10D331.


Agonist-specific patterns of beta 2-adrenoceptor responses in human airway cells during prolonged exposure.

Düringer C, Grundström G, Gürcan E, Dainty IA, Lawson M, Korn SH, Jerre A, Håkansson HF, Wieslander E, Fredriksson K, Sköld CM, Löfdahl M, Löfdahl CG, Nicholls DJ, Silberstein DS.

Br J Pharmacol. 2009 Sep;158(1):169-79. doi: 10.1111/j.1476-5381.2009.00262.x. Epub 2009 Jun 22.


The effect of different lung densities on the accuracy of various radiotherapy dose calculation methods: implications for tumour coverage.

Aarup LR, Nahum AE, Zacharatou C, Juhler-Nøttrup T, Knöös T, Nyström H, Specht L, Wieslander E, Korreman SS.

Radiother Oncol. 2009 Jun;91(3):405-14. doi: 10.1016/j.radonc.2009.01.008. Epub 2009 Mar 16.


In-vessel activation monitors in JET: progress in modeling.

Bonheure G, Lengar I, Syme B, Wieslander E, Hult M, Gasparro J, Marissens G, Arnold D, Laubenstein M, Popovichev S; JET-EFDA Contributors.

Rev Sci Instrum. 2008 Oct;79(10):10E504.


Experience from long-term monitoring of RAKR ratios in (192)Ir brachytherapy.

Carlsson Tedgren A, Bengtsson E, Hedtjärn H, Johansson A, Karlsson L, Lamm IL, Lundell M, Mejaddem Y, Munck Af Rosenschöld P, Nilsson J, Wieslander E, Wolke J.

Radiother Oncol. 2008 Nov;89(2):217-21. doi: 10.1016/j.radonc.2008.07.024. Epub 2008 Sep 4.


Expression of genes involved in oxidative stress responses in airway epithelial cells of smokers with chronic obstructive pulmonary disease.

Pierrou S, Broberg P, O'Donnell RA, Pawłowski K, Virtala R, Lindqvist E, Richter A, Wilson SJ, Angco G, Möller S, Bergstrand H, Koopmann W, Wieslander E, Strömstedt PE, Holgate ST, Davies DE, Lund J, Djukanovic R.

Am J Respir Crit Care Med. 2007 Mar 15;175(6):577-86. Epub 2006 Dec 7.


Comparison of dose calculation algorithms for treatment planning in external photon beam therapy for clinical situations.

Knöös T, Wieslander E, Cozzi L, Brink C, Fogliata A, Albers D, Nyström H, Lassen S.

Phys Med Biol. 2006 Nov 21;51(22):5785-807. Epub 2006 Oct 24.


Novel conserved hydrolase domain in the CLCA family of alleged calcium-activated chloride channels.

Pawłowski K, Lepistö M, Meinander N, Sivars U, Varga M, Wieslander E.

Proteins. 2006 May 15;63(3):424-39.


Dose response evaluation of a low-density normoxic polymer gel dosimeter using MRI.

Haraldsson P, Karlsson A, Wieslander E, Gustavsson H, Bäck SA.

Phys Med Biol. 2006 Feb 21;51(4):919-28. Epub 2006 Feb 1.


Cigarette smoke extract modulates respiratory defence mechanisms through effects on T-cells and airway epithelial cells.

Glader P, Möller S, Lilja J, Wieslander E, Löfdahl CG, von Wachenfeldt K.

Respir Med. 2006 May;100(5):818-27. Epub 2005 Oct 19.


Transforming growth factor-beta 1 specifically induce proteins involved in the myofibroblast contractile apparatus.

Malmström J, Lindberg H, Lindberg C, Bratt C, Wieslander E, Delander EL, Särnstrand B, Burns JS, Mose-Larsen P, Fey S, Marko-Varga G.

Mol Cell Proteomics. 2004 May;3(5):466-77. Epub 2004 Feb 6.


A virtual linear accelerator for verification of treatment planning systems.

Wieslander E, Knöös T.

Phys Med Biol. 2000 Oct;45(10):2887-96.


Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line In vitro.

Wieslander E, Delander EL, Järkelid L, Hjertberg E, Tunek A, Brattsand R.

Am J Respir Cell Mol Biol. 1998 Sep;19(3):477-84.


Antioxidative properties of organotellurium compounds in cell systems.

Wieslander E, Engman L, Svensjö E, Erlansson M, Johansson U, Linden M, Andersson CM, Brattsand R.

Biochem Pharmacol. 1998 Mar 1;55(5):573-84.


Budesonide inhibits T cell-initiated epithelial pathophysiology in an in vitro model of inflammation.

McKay DM, Brattsand R, Wieslander E, Fung M, Croitoru K, Perdue MH.

J Pharmacol Exp Ther. 1996 Apr;277(1):403-10.


Cytotoxicity of human phagocytes studied in vitro in a novel model based on neutral red absorbtion.

Brattsand R, Delander EL, Peterson C, Wieslander E.

Agents Actions. 1991 Sep;34(1-2):35-7.


Effects of oral N-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers.

Linden M, Wieslander E, Eklund A, Larsson K, Brattsand R.

Eur Respir J. 1988 Jul;1(7):645-50.


Human alveolar macrophages from smokers have an impaired capacity to secrete LTB4 but not other chemotactic factors.

Wieslander E, Linden M, Håkansson L, Eklund A, Blaschke E, Brattsand R, Venge P.

Eur J Respir Dis. 1987 Oct;71(4):263-72.


Sarcoidosis in an apparently healthy volunteer.

Eklund A, Blaschke E, Persson U, Wieslander E.

Chest. 1986 Apr;89(4):615.


Importance of particulate antigen for the induction of dual bronchial reaction in guinea-pigs.

Wieslander E, Andersson P, Linden M, Axelsson B, Källström L, Brattsand R, Paulsson I.

Agents Actions. 1985 Mar;16(1-2):37-8.


Supplemental Content

Loading ...
Support Center